Follow Us:
Ophthalmologists, Retina Specialists
Diabetic Retinopathy
Julia A. Haller, MD
Ophthalmologist-in-Chief
Wills Eye Hospital
Chair and Professor
Department of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Julia A. Haller, MD, is Ophthalmologist-in-Chief of Wills Eye Hospital, where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and Co-Director of the Wills Vision Research Center at Jefferson.
Dr Haller was educated at the Bryn Mawr School in Baltimore, Princeton University, and Harvard Medical School. After a Halsted surgical internship at Johns Hopkins and a fellowship in ocular pathology with Frederick A. Jakobiec, MD, at Manhattan Eye, Ear and Throat Hospital, she completed her residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins. She received a Heed Fellowship award for her retina training at Hopkins, directed by Ronald G. Michels, MD. She then became Wilmer’s first female Chief Resident, joined the faculty thereafter, and was named the inaugural Katharine Graham Professor of Ophthalmology in 2002, and the inaugural Robert Bond Welch, MD, Professor of Ophthalmology in 2006. At Wilmer, she directed the Retina Fellowship Training Program. She assumed leadership of the Wills Eye Hospital in 2007.
Dr Haller’s honors include the Bryn Mawr School scholarship award for valedictorian, a National Merit Scholarship, her A.B. in philosophy magna cum laude, Alpha Omega Alpha, the American Academy of Ophthalmology (AAO) Honor Award, the Rolex Achievement Award (to a past participant in collegiate varsity lacrosse), the AAO Senior Achievement Award, the Vitreous Society Senior Honor Award, the Crystal Apple Award of the American Society of Retina Specialists (ASRS) for teaching and mentorship, the Kreissig Award from EURETINA, the President’s Award from Women in Ophthalmology, a Secretariat Award from the AAO, the Gertrude Pyron Award from the Retina Research Foundation/ASRS, a Lifetime Achievement Award from the AAO, the Louis Braille Award from Associated Services for the Blind and the Heed Award from the Society of Heed Fellows.
Dr Haller has published more than 300 scientific articles and book chapters. One of the world’s most renowned retina surgeons and invited lecturers, she has a particular research interest in retinal pharmacology, macular surgery, retinal venous occlusive disease, diabetic retinopathy, age-related macular degeneration, the repair of complicated retinal detachments, and health care disparities, currently serving as principal investigator on $9m in government grant-funded projects.
Dr Haller is president of the Retina Society, past president of the American Society of Retina Specialists, and president-elect of the Board of Trustees of the Association of University Professors of Ophthalmology. She is an editorial board member of the publications RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, Ophthalmology Times, EyeWorld, and Evidence-Based Eye Care.
A member of numerous scientific advisory boards and data and safety monitoring committees, she is also a past member of the Boards of Trustees of Princeton University and the Bryn Mawr School in Baltimore, and has served as a consultant to Walter Reed Army Medical Center. She currently sits on the Boards of the ARVO Foundation for Eye Research, Women in Retina, the Foundation for The History of Women in Medicine, the Harvard Medical School Alumni Council, and the Johns Hopkins Medical and Surgical Association.
Sunir J. Garg, MD
Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Attending Physician
Retina Service
Wills Eye Hospital
Philadelphia, Pennsylvania
Sunir J. Garg, MD, is an attending physician on the Retina Service at Wills Eye Hospital. His clinical interests include advanced treatments for diabetic retinopathy, age-related macular degeneration, complex retinal detachments, retinal vascular diseases, surgical diseases of the macula and retina, and ocular inflammation. Dr Garg is listed among "The Best Ophthalmologists" in the United States.
He is a Fellow of both the American College of Surgeons and American Academy of Ophthalmology, and is an active member of the Retina Society, the Macula Society, the American Society of Retinal Specialists, the Pennsylvania Academy of Ophthalmology, the American Uveitis Society and the Association for Research in Vision and Ophthalmology. He is past president of the Greater Philadelphia Ophthalmic Society.
Dr Garg has been invited to speak both nationally and internationally. In addition to being the editor of one textbook and co-editor of two others, he has authored more than 100 papers and book chapters, and serves as a manuscript reviewer for a number of prestigious journals. He is also a consultant to the American College of Physicians and the Wills Eye Manual. He is editor of ophthalmology for the Merck Manual, Retina Committee Chair for the American Academy of Ophthalmology ONE Network and is Editor-in-Chief for Retina Times, an official publication of the American Society of Retina Specialists.
Dr. Garg has been the course director for an honored vitreoretinal surgery course at the American Academy of Ophthalmology and received an award from the American Retina Foundation for his research on macular degeneration. He also serves as principal investigator on several major national and international clinical trials.
SriniVas R. Sadda, MD
President and Chief Scientific Officer
Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair
Doheny Eye Institute
Professor of Ophthalmology
University of California, Los Angeles
Los Angeles, California
SriniVas R. Sadda, MD, is the President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan-Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California, Los Angeles, Geffen School of Medicine. He received his medical degree from Johns Hopkins University, where he also completed ophthalmology residency and neuro-ophthalmology and medical retina fellowships (Wilmer Eye Institute).
Dr Sadda’s major research interests include automated retinal image analysis, retinal substructure assessment, and advanced retinal imaging technologies. He has more than 380 peer-reviewed publications and 13 book chapters, and has given more than 350 presentations worldwide. Dr Sadda also serves as an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Graefe’s, Ophthalmology Retina, and Ophthalmology. He is also an editor of the 5th edition of the Ryan’s Retina textbook. Among Dr Sadda’s awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, an Achievement Award and a Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, the Macula Society Young Investigator Award, Asia-Pacific Academy of Ophthalmology Achievement Award, The Macula Society Paul Henkind Lecture and Award, and American Society of Retina Specialists Young Investigator Award. He has also received the Silver Fellow designation from the Association for Research in Vision and Ophthalmology. He has been named to the Best Doctors of America list for several consecutive years.
Charles C. Wykoff, MD, PhD
Director of Research
Retina Consultants of Houston
Blanton Eye Institute
Houston Methodist Hospital
Clinical Associate Professor of Ophthalmology
Weill Cornell Medical College
Houston, Texas
Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.
Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.
1. | Evaluate the evidence supporting treatment for preventing vision-threatening outcomes in diabetic retinopathy | 2. | Design treatment plans for diabetic retinopathy that consider individual patient factors |
3. | Describe clinical trial data supporting treatment of moderate-to-severe nonproliferative diabetic retinopathy to prevent proliferative diabetic retinopathy and diabetic macular edema | 4. | Integrate imaging and communication tools into practice to help patients prevent vision loss due to diabetic retinopathy |
1. | Evaluate the evidence supporting treatment for preventing vision-threatening outcomes in diabetic retinopathy |
2. | Design treatment plans for diabetic retinopathy that consider individual patient factors |
3. | Describe clinical trial data supporting treatment of moderate-to-severe nonproliferative diabetic retinopathy to prevent proliferative diabetic retinopathy and diabetic macular edema |
4. | Integrate imaging and communication tools into practice to help patients prevent vision loss due to diabetic retinopathy |
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Wills Eye Hospital and MedEdicus LLC. Wills Eye Hospital is accredited by the ACCME to provide continuing medical education for physicians.
Instructions & Registration
This course takes approximately 1.5 hours. Please read the monograph, consulting any additional references if needed. Once the materials have been reviewed, complete the post test and evaluation found at the end of the activity, after which you will be able to generate your CME certificate.
Disclosure
As a provider accredited by the ACCME, Wills Eye Hospital must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in this CME activity were asked to disclose the following:
Disclosures
CME Reviewer: Ralph C. Eagle Jr, MD, has no relevant financial relationships with any commercial interests.
Faculty:
Dr Sunir J. Garg is a consultant for Bausch & Lomb Incorporated; Deciphera Pharmaceuticals, Inc; Johnson & Johnson Vision Care, Inc; and TopiVert Ltd; and a contracted researcher for Aerpio Therapeutics; Allergan; Apellis Pharmaceuticals; and Wills Eye Hospital.
Dr Julia A. Haller is a consultant for KalVista Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Spark Therapeutics, Inc; board member of Celgene Corporation; and a data safety monitoring board member of Aura Biosciences, Inc; and Janssen Global Services, LLC.
Dr SriniVas R. Sadda is a consultant for Allergan; Amgen; Bayer Corporation; CenterVue SpA; Eyenuk, Inc (past); F. Hoffman-La Roche Ltd; Genentech, Inc; Heidelberg Engineering GmbH; Novartis Pharmaceuticals Corporation; Optos; and 4DMT; and received other funding (research instruments) from Carl Zeiss Meditec, Inc; CenterVue SpA; Heidelberg Engineering GmbH; NIDEK Inc; Optos; and Topcon Medical Systems, Inc.
Dr Charles C. Wykoff is a consultant for Adverum; Aerpio Therapeutics; Alimera Sciences; Allegro Ophthalmics, LLC; Allergan; Apellis Pharmaceuticals; Bayer Corporation; Clearside Biomedical, Inc; D.O.R.C.; EyePoint Pharmaceuticals; F. Hoffmann-La Roche Ltd; Genentech, Inc; IVERIC bio; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; ONL Therapeutics; Polyphotonix; Recens Medical Co, Ltd; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; Shanghai Fosun Pharmaceutical (Group) Co, Ltd; and Takeda Pharmaceuticals USA, Inc; and is a contracted researcher for Adverum; Aerpio Therapeutics; Allergan; Apellis Pharmaceuticals; Chengdu Kanghong Pharmaceuticals Group Co, Ltd; Clearside Biomedical, Inc; F. Hoffmann-La Roche Ltd; Genentech, Inc; IVERIC bio; Kodiak Sciences Inc; Neurotech Pharmaceuticals; Novartis Pharmaceuticals Corporation; Opthea; Recens Medical Co, Ltd; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Samsung; and Santen Inc.
Planning Committee: The faculty have relevant commercial relationships as described above.
Commercial Support
This activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
Special Services
If you need special accommodations because of a disability or for an alternative form of course materials, please contact us at continuingeducation@willseye.org or (215) 440-3168. Wills Eye Hospital fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof.
Provider Contact Information
For questions about the CME activity content, please contact Wills Eye Hospital at continuingeducation@willseye.org or (215) 440-3168.
Privacy Policy
All information provided by course participants is confidential and will not be shared with any other parties for any reason without permission.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Wills Eye Hospital, MedEdicus LLC, or Regeneron Pharmaceuticals, Inc.
Media
Internet
COURSE VIEWING REQUIREMENTS
Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |